FDA Approves VANFLYTA — Daiichi Sankyo Inc.

# FDA Approves Daiichi Sankyo's VANFLYTA (quizartinib) for FLT3-Mutated Acute Myeloid Leukemia Daiichi Sankyo Inc. announced FDA approval of VANFLYTA (quizartinib dihydrochloride), an oral FLT3 inhibitor expected to strengthen the company's oncology portfolio and capture market share in the estimated $2+ billion AML therapeutics segment. The approval positions Daiichi Sankyo to compete with existing FLT3-targeting treatments